<DOC>
	<DOCNO>NCT00172016</DOCNO>
	<brief_summary>The purpose study assess efficacy tolerability zoledronic acid prevent skeletal-related event patient prostate cancer</brief_summary>
	<brief_title>A Study Evaluate Efficacy Tolerability Zoledronic Acid Patients With Metastatic Prostate Cancer Who Can Treated With Group Medications Known Bisphosphonates</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Written informed consent must obtain Age &gt; 18 year Histologically confirm diagnosis carcinoma prostate Current ( previous ) objective evidence metastatic disease bone Currently receive 1st line hormonal therapy LHRH agonists hormonal treatment ECOG performance status 0 , 1 , 2 Patients abnormal renal function evidence either serum creatinine determination 1.5 x great upper limit normal calculated creatinine clearance 60 ml/minute less Corrected ( adjust serum albumin ) serum calcium concentration &lt; 8.0 mg/dl ( 2.00 mmol/L ) WBC &lt; 3.0x1'000'000'000 , ANC &lt; 1500/mm3 , Hgb &lt; 8.0 g/dL , platelet &lt; 75 x 1'000'000'000/L . Liver function test &gt; 2.5 ULN , serum creatinine &gt; 1.5 ULN . Patients another nonmalignant disease would confound evaluation primary endpoint prevent patient comply protocol . Known hypersensitivity zoledronic acid bisphosphonates Subjects , opinion investigator , unlikely cooperate fully study Other protocoldefined inclusion / exclusion criterion apply .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Zoledronic acid</keyword>
	<keyword>SRE</keyword>
	<keyword>Prostate cancer</keyword>
</DOC>